{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:47:57Z","timestamp":1781920077281,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,11]]},"DOI":"10.1093\/ibd\/izaa034","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T09:59:31Z","timestamp":1582365571000},"page":"e38-e40","source":"Crossref","is-referenced-by-count":2,"title":["Toxic Epidermal Necrolysis Because of Various Herpesviruses Infection After Accelerated Infliximab Induction in a Chinese Patient With Acute Severe Ulcerative Colitis"],"prefix":"10.1093","volume":"26","author":[{"given":"Hui","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"2020041111454013500_CIT0001","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J."},{"key":"2020041111454013500_CIT0002","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2020041111454013500_CIT0003","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"2020041111454013500_CIT0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/apt.12387","article-title":"Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients","volume":"38","author":"Sj\u00f6berg","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2020041111454013500_CIT0005","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/S0016-5085(12)61457-7","article-title":"Accelerated clearance of infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure","volume":"142","author":"Kevans","year":"2012","journal-title":"Gastroenterology."},{"key":"2020041111454013500_CIT0006","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020041111454013500_CIT0007","doi-asserted-by":"crossref","first-page":"S803","DOI":"10.1016\/S0016-5085(16)32720-2","article-title":"Comparison of accelerated infliximab induction vs standard induction treatment in acute severe ulcerative colitis","volume":"150","author":"Choy","year":"2016","journal-title":"Gastroenterology."},{"key":"2020041111454013500_CIT0008","first-page":"121","article-title":"Accelerated dosing of infliximab induction and endoscopic mucosal healing in patients with acute severe ulcerative colitis","volume":"32","author":"An","year":"2017","journal-title":"J Gastroenterol Hepatol."},{"key":"2020041111454013500_CIT0009","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S0016-5085(16)30462-0","article-title":"Accelerated dosing of infliximab prevents colectomy within 90 days in only half of patients with severe ulcerative colitis","volume":"150","author":"Govani","year":"2016","journal-title":"Gastroenterology."},{"key":"2020041111454013500_CIT0010","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ibd\/izx039","article-title":"Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis","volume":"24","author":"Shah","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2020041111454013500_CIT0011","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020041111454013500_CIT0012","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med."},{"key":"2020041111454013500_CIT0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol."},{"key":"2020041111454013500_CIT0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/ACI.0b013e3283630cc2","article-title":"Toxic epidermal necrolysis: the year in review","volume":"13","author":"Lee","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"2020041111454013500_CIT0015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J Dermatol."},{"key":"2020041111454013500_CIT0016","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.3748\/wjg.15.4449","article-title":"Stevens-Johnson syndrome complicating adalimumab therapy in Crohn\u2019s disease","volume":"15","author":"Salama","year":"2009","journal-title":"World J Gastroenterol."},{"key":"2020041111454013500_CIT0017","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol."},{"key":"2020041111454013500_CIT0018","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/00015550510037062","article-title":"Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab","volume":"85","author":"Al-Shouli","year":"2005","journal-title":"Acta Derm Venereol."},{"key":"2020041111454013500_CIT0019","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol."},{"key":"2020041111454013500_CIT0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J Dermatol."},{"key":"2020041111454013500_CIT0021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00002018-200225130-00006","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years\u2019 experience","volume":"25","author":"Forman","year":"2002","journal-title":"Drug Saf."},{"key":"2020041111454013500_CIT0022","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1084\/jem.182.6.1703","article-title":"T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen","volume":"182","author":"Burrows","year":"1995","journal-title":"J Exp Med."},{"key":"2020041111454013500_CIT0023","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2009-05-222596","article-title":"Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-\/nonself-recognition","volume":"114","author":"Rist","year":"2009","journal-title":"Blood."},{"key":"2020041111454013500_CIT0024","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2005-07-2702","article-title":"Epstein-Barr virus: the impact of scientific advances on clinical practice","volume":"107","author":"Williams","year":"2006","journal-title":"Blood."},{"key":"2020041111454013500_CIT0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2015.05.027","article-title":"Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy","volume":"136","author":"Wheatley","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"2020041111454013500_CIT0026","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med."},{"key":"2020041111454013500_CIT0027","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/all.12410","article-title":"The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome","volume":"69","author":"Ishida","year":"2014","journal-title":"Allergy."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/e38\/33035353\/izaa034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/5\/e38\/33035353\/izaa034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:31:47Z","timestamp":1695814307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/5\/e38\/5748143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,22]]},"published-print":{"date-parts":[[2020,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa034","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,22]]}}}